TB Alliance-Lupin Deal To Improve Pretomanid Access But India Unlikely To Benefit For Now
Viatris Has Capacity To Meet Demand
While Viatris says it has sufficient capacity to meet current and future demand for tuberculosis drug pretomanid, TB Alliance has signed a non-exclusive license with Lupin. This is the second tie-up with an Indian manufacturer but the local restricted use approval means countries other than India are likely to benefit for now.